Bacil Pharma plans to raise up to ₹50 crore via a rights issue, increasing authorized capital to ₹65 crore. Two independent directors have resigned.
Bacil Pharma Plans ₹50 Crore Rights Issue, Boosts Authorized Capital
Bacil Pharma Limited will raise up to ₹50 crore through a rights issue and has increased its authorized share capital to ₹65 crore.
Reader Takeaway: Capital infusion via rights issue; governance concerns with director resignations.
What just happened
Bacil Pharma's board has approved a significant move to raise funds by launching a rights issue of up to ₹50 crore. To support this, the company's authorized share capital has been increased by ₹45 crore, bringing the total to ₹65 crore from the previous ₹20 crore.
Why this matters
The rights issue aims to bring in fresh capital for the company's operations. Shareholders will have the opportunity to subscribe to new shares, potentially diluting existing holdings if not fully subscribed. The increase in authorized capital is a necessary step for this fundraising.
The backstory
Bacil Pharma has a history of fundraising activities to support its growth. The current move is part of its ongoing strategy to strengthen its financial base.
What changes now
A 'Right Issue Committee' has been formed, comprising Ms. Chaitali Kalpataru Shah (Chairman), Mr. Vivek Mukesh Yadav, and Mr. Omprakash Pyarelal Sonar, to manage the rights issue process. Key terms like issue price and entitlement ratio are to be finalized.
Risks to watch
The simultaneous resignation of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, raises governance questions. Investors should watch for disclosures on the reasons for these departures and their potential impact.
Peer comparison
Companies in the pharmaceutical sector often tap equity markets for capital to fund expansion, R&D, or working capital needs. Rights issues are a common method, though market conditions and company performance influence their success.
Context metrics (time-bound)
The company plans to raise up to ₹50 crore through the rights issue.
Authorized capital will increase from ₹20 crore to ₹65 crore, a ₹45 crore hike.
What to track next
Investors should closely monitor the announcement of the rights issue's specifics, including the issue price, record date, and entitlement ratio. Additionally, any further information regarding the board changes and new appointments will be crucial.